Lifeward Announces Closing of $2.6 Million Public Offering

Rhea-AI Summary

Lifeward (NASDAQ: LFWD), a medical technology company, has closed its previously announced public offering, raising $2.6 million through the sale of 4,000,000 ordinary shares at $0.65 per share. The offering includes warrants to purchase an additional 4,000,000 ordinary shares at an exercise price of $0.65, potentially providing another $2.6 million if fully exercised.

The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which was conducted under an effective SEC registration statement.

Positive

• Secured $2.6 million in immediate funding through public offering
• Potential for additional $2.6 million through warrant exercises
• Strengthened balance sheet for commercial efforts and operations

Negative

• Significant dilution to existing shareholders with 4 million new shares
• Low offering price of $0.65 per share indicates weak market position
• Additional potential dilution from 4 million warrants

Insights

Financial Analyst

Lifeward raised $2.6M in a dilutive offering at $0.65/share with warrants, signaling potential financial strain despite securing needed capital.

Lifeward has closed a $2.6 million public offering that merits careful analysis. The structure of this financing—4 million ordinary shares with accompanying warrants at just $0.65 per share—suggests challenging financial circumstances. Each share comes with a warrant exercisable at the same price, potentially bringing in another $2.6 million if all warrants are exercised, though this is far from guaranteed.

The pricing reveals concerning signals about Lifeward's current position. The $0.65 share price indicates either significant market discount or reflects a company facing difficulties. This capital raise represents substantial dilution for existing shareholders, as 4 million new shares have entered circulation.

While securing $2.6 million provides immediate working capital for commercial efforts and operations, the terms suggest Lifeward had limited financing options. The placement agent structure with H.C. Wainwright, rather than a traditional underwritten offering, typically indicates smaller, more challenging fundraising situations.

For a NASDAQ-listed medical technology company, this relatively modest sum and the warrant structure point to near-term cash needs rather than strategic growth capital. Investors should monitor Lifeward's burn rate and operational progress to assess whether this funding provides sufficient runway for meaningful business advancement or merely delays more fundamental financial challenges.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants have an exercise price of $0.65 per ordinary share, are exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $2.6 million before deducting the placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the ordinary warrants, if fully exercised on a cash basis, will be approximately $2.6 million. No assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from this offering for its continuing commercial efforts, working capital and general corporate purposes.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-288172), as amended, which was declared effective by the Securities and Exchange Commission (the "SEC") on June 25, 2025. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Lifeward Ltd.

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include statements related to the intended use of proceeds from the offering, the exercise of the ordinary warrants prior to their expiration and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements, including risks and uncertainties related to market conditions, are more fully discussed in the Company’s periodic filings with the SEC, including the risk factors described under the heading "Risk Factors" in the Company’s annual report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 7, 2025 and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:
Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward Ltd.
E: media@golifeward.com

Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: ir@golifeward.com

FAQ

How much did Lifeward (LFWD) raise in its June 2025 public offering?

Lifeward raised $2.6 million through the sale of 4,000,000 ordinary shares at $0.65 per share, with potential for an additional $2.6 million if all warrants are exercised.

What is the exercise price of LFWD's warrants from the June 2025 offering?

The warrants have an exercise price of $0.65 per ordinary share and are exercisable immediately, expiring five years from the issuance date.

How will Lifeward use the proceeds from its $2.6M offering?

Lifeward intends to use the net proceeds for continuing commercial efforts, working capital, and general corporate purposes.

Who was the placement agent for Lifeward's June 2025 offering?

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

What is the potential dilution from LFWD's June 2025 offering?

The offering includes 4 million new ordinary shares plus warrants for an additional 4 million shares, potentially resulting in significant dilution for existing shareholders.